Lastly, we revealed a substantial amount of concordantly upregulated proteins to be associated with one or more FDA-approved drugs, among which was the validated protein, MAOB, encouraging drug repurposing for meningioma treatment. The gene discussed is MAOB; the disease is meningioma.